Nov 19 (Reuters) - Cytokinetics Inc CYTK.O:
CYTOKINETICS AND BAYER ANNOUNCE EXCLUSIVE LICENSING COLLABORATION FOR AFICAMTEN IN JAPAN
CYTOKINETICS INC - TO RECEIVE €50 MILLION UPFRONT, UP TO €90 MILLION IN MILESTONES
CYTOKINETICS INC - ELIGIBLE FOR UP TO €490 MILLION IN COMMERCIAL MILESTONES
CYTOKINETICS INC - BAYER TO CONDUCT PHASE 3 TRIAL IN JAPANESE PATIENTS WITH OBSTRUCTIVE HCM
Source text: ID:nGNXsZdWX
Further company coverage: CYTK.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.